Cargando…

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use

Major obstetric haemorrhage remains a significant cause of maternal morbidity and mortality. Previous case reports suggest the potential benefit of recombinant activated factor VII (rFVIIa: NovoSeven(R)) as a haemostatic agent. We performed a retrospective review of the use of rVIIa in major obstetr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bomken, Charlotte, Mathai, Sue, Biss, Tina, Loughney, Andrew, Hanley, John
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817503/ https://www.ncbi.nlm.nih.gov/pubmed/20148069 http://dx.doi.org/10.1155/2009/364843

Ejemplares similares

Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven(®)) in obstetrical haemorrhagic shock
por: Sobieszczyk, S, et al.
Publicado: (2003)

Nebulised recombinant activated factor VII (rFVIIa) does not attenuate the haemorrhagic effects of blast lung injury
por: Smith, Jason E, et al.
Publicado: (2019)

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
por: Aggarwal, Anita, et al.
Publicado: (2004)

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience
por: Shah, Nurfatin Mohd, et al.
Publicado: (2018)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

Regional variation of the off-licence use of rFVIIa for patients with uncontrolled haemorrhage in England
por: Spivey, MH, et al.
Publicado: (2010)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Recombinant activated factor VII (rFVIIa-NovoSeven(®)-NovoNordisk) treatment of bleeding complications in intensive care unit
por: Bonadona, A, et al.
Publicado: (2002)

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy
por: Nicosia, Dario, et al.
Publicado: (2019)

Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors
por: Milošević, Danko, et al.
Publicado: (2014)

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment
por: Montacir, Othman, et al.
Publicado: (2018)

Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
por: Milanov, S, et al.
Publicado: (2003)

Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven(®)) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial
por: Thabut, D, et al.
Publicado: (2004)

Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)
por: Rajpurkar, Madhvi, et al.
Publicado: (2019)

Neonatal thrombocytopenia: Thrombin generation in presence of reduced platelet counts and effects of rFVIIa in cord blood
por: Haidl, Harald, et al.
Publicado: (2019)

Use of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injury
por: Kim, Bobby, et al.
Publicado: (2014)

Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa)
por: Kyang, Lee S., et al.
Publicado: (2019)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) – a review of a new treatment paradigm
por: Heslet, Lars, et al.
Publicado: (2012)

Treatment of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus Patient With Local Pulmonary Administration of Factor VIIa (rFVIIa): A Case Report
por: Alabed, Iehab B.
Publicado: (2014)

Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report
por: Ma, Hongbing, et al.
Publicado: (2021)

Thromboelastometry as an Ancillary Tool for Evaluation of Coagulation Status after rFVIIa Therapy in a Pregnant Woman with Severe Hypoproconvertinemia—A Case Series and Review of the Literature
por: Krzyżanowski, Arkadiusz, et al.
Publicado: (2022)

Recombinant activated factor VII in post partum haemorrhage
por: Magon, Navneet, et al.
Publicado: (2013)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Treatment of obstetric hemorrhage with recombinant activated factor VII
por: Czuprynski, P, et al.
Publicado: (2009)

Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
por: Kluger, Yoram, et al.
Publicado: (2007)

Management of major obstetric haemorrhage
por: Trikha, Anjan, et al.
Publicado: (2018)

A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths
por: Rossaint, R, et al.
Publicado: (2005)

Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report
por: Vlachos, Konstantinos, et al.
Publicado: (2008)

Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience
por: Morel, Nicolas, et al.
Publicado: (2012)

Overview of the human pharmacokinetics of recombinant activated factor VII
por: Klitgaard, Thomas, et al.
Publicado: (2008)

Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories
por: Estella, Ángel, et al.
Publicado: (2008)

Guidelines-associated decrease in mortality with recombinant activated factor VII for refractory hemorrhage
por: Schneider, AS, et al.
Publicado: (2009)

Acquired hemophilia in a 7‐year‐old girl successfully treated with recombinant FVIIA and steroids: A case report
por: Giuffrida, Gaetano, et al.
Publicado: (2020)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

The MOTHER (Major Obstetric Trauma or Haemorrhage EmeRgency) guideline: development of an algorithm for emergency department management of trauma in pregnancy
por: Borgeaud, Nathan, et al.
Publicado: (2015)

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital
por: Spivey, M, et al.
Publicado: (2009)

Massive blood transfusion for obstetric haemorrhage
por: Simmons, S, et al.
Publicado: (2013)

N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits
por: Chevreux, Guillaume, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pf700mjr2kr39fglguon5pqkdv